Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Axitinib in Advanced Kidney Cancer and Melanoma
NCT03086174Phase 1Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in kidney cancer and melanoma, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events at 3 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
kidney cancermelanoma
Beyond the preview
Go deeper on NCT03086174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086174.